CA-VERACODE
1.5.2024 14:51:32 CEST | Business Wire | Press release
Veracode, a global leader in application risk management, today announced platform innovations that set a new standard for developer-powered application security. New repo risk visibility and analysis from Longbow Security, powered by Veracode, speeds up remediation of application risk from code repositories to runtime images. The solution launches alongside Veracode Fix in the Integrated Development Environment (IDE) and Batch Fix to bridge the gap between development and security teams. These latest innovations help developers focus on the most critical tasks that drive value and differentiation.
“Developers today face significant competing pressures to innovate faster and perform more security checks on their code than ever before,” said Tim Jarrett, Group Head of Product Management at Veracode. “We are committed to a frictionless experience for developers and security operators and our latest product enhancements make the job of securing code simple and seamless.”
Bringing Developer & Security Teams Together: Repo Risk Visibility & Analysis
In April, Veracode acquired Longbow Security to help organizations effectively manage and reduce application risk across the growing attack surface. The integration of Longbow’s newest capability, repo risk visibility and analysis, bridges the gap between development and security teams with enhanced visibility from code repositories to cloud assets and runtime images. It also illuminates infrastructure-as-code and misconfiguration risk for cloud assets originating from repositories.
“Customers challenged us to apply our unique cloud risk and prioritization expertise from Longbow to problems they face managing upstream risk in their code repositories,” said Derek Maki, Vice President of Product Management at Veracode. “We responded with a solution that gives visibility into the relationship between source code weaknesses and runtime security posture. Simultaneously, development teams get a consolidated view of risk and huge time savings when it comes to prioritizing remediation, reducing code changes, and fixing issues fast.”
This new feature complements Veracode’s latest innovation for GitHub repo scanning, which enables developers to streamline activities like staging servers and environments so they don’t need to scan every time. This makes it easier for development and security teams to collaborate on secure coding and scanning as Veracode results are delivered to GitHub where developers can act immediately.
Security Debt Reduction: Veracode Fix in the IDE & Batch Fix
Research shows 92 percent of U.S.-based developers are already using artificial intelligence (AI) coding tools both in and outside of work, with generative AI helping software engineers write code 35-45 percent faster. At the same time, other research suggests code developed by AI contains the same percentage of security flaws as that generated by humans.
Veracode was the first company to deliver a solution that provides developers with AI-generated secure code fixes. Since launching Veracode Fix at RSA Conference last year, hundreds of customers have used the solution to reduce their backlog of security debt and risk. Ninety-two percent of CWEs (Common Weakness Enumeration) with a severity rating from medium to very high can be addressed through AI-generated code edits from Veracode Fix.
With the introduction of Veracode Fix in the IDE, developers can now fix flaws faster with AI-suggested remediation right in the IDE, without switching applications or researching alternative code options. Fixes can be made before code is pushed through the software development lifecycle, dramatically cutting the time and cost spent fixing flaws compared to retroactive remediation.
Batch Fix enables bulk AI-assisted remediation of flaws in source code across multiple flaws and files in one operation. This makes remediation of flaws an order of magnitude faster, aiding the reduction of security debt at scale. For example, developers can use it to fix a CWE that requires an easy-to-test resolution and run it across multiple source files at once.
Jarrett closed, “With these latest innovations, Veracode meets developers where they are—in the tools they use daily—to help them secure the code they create today, without compromising productivity. This vastly improves efficiency and velocity, fostering a culture of collaboration and trust between development and security teams.”
Repo Risk Visibility & Analysis, Veracode Fix in the IDE, and Batch Fix are available immediately. For more information, please visit the Veracode blog.
Visitors to RSA Conference can learn more about Veracode’s platform and these new features by visiting Veracode’s booth #2045 in the main hall.
About Veracode
Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, and Penetration Testing.
Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and Twitter.
Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501107223/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom